Views for collaboration between pharmaceutical industry and academia a haapal...Antti Haapalinna
The document discusses views on collaboration between the pharmaceutical industry and academia from Antti Haapalinna, Vice President of Research and Development at Orion Corporation. It notes that strategic partnerships can cover the entire R&D chain from early discovery to late-stage clinical development and marketing. Early-stage partnerships are often with smaller organizations that provide specific expertise to complement larger companies. Later-stage partnerships are usually with larger organizations for their clinical trial expertise and global reach. Key success factors include a mutual desire to develop new treatments, each party contributing unique capabilities, and professionally coordinated collaboration.
ttopstart academy - getting NIH funding as a European researcher or companyttopstart B.V.
The NIH spends a lot of its research funding abroad, amongst which a significant portion in Europe. This presentation provides guidance for non-US entities to attract NIH funding.
This document provides information about an upcoming conference on managing partnerships with contract research organizations (CROs). The conference will take place on October 3-4, 2012 in London and will include presentations from pharmaceutical companies and CROs on trends in clinical development outsourcing, developing effective CRO partnerships, and managing regulatory inspections of CRO activities. Pre-conference workshops on October 2 will focus on defining the scope of CRO relationships and ensuring quality in CRO engagements. Key speakers are listed from pharmaceutical companies like Pfizer, Eli Lilly and AstraZeneca and CROs like Quintiles. The document outlines the conference agenda and encourages those in clinical development, outsourcing, and related areas to attend.
Preparing for a career inthe pharmaceutical industryMentLife
The document provides information about preparing for a career in the pharmaceutical industry. It discusses the pros and cons of working in the industry, some key statistics about the industry, and how the industry is changing and responding to challenges. It provides tips for how to prepare for an interview, improve chances of getting a job, and what skills are needed at different stages of the research and development process. The industry is still profitable but facing pressures to reduce costs through consolidation and outsourcing while demand for new drugs grows.
This document discusses strategies for pharmaceutical research and development (R&D) and drug development. Some key points:
- Developing a new drug takes 15-16 years on average and costs around $800 million, with 75% of costs attributed to high failure rates. Only 1 in 5-10 drugs that enter development make it to market.
- Patent protection is important for pharmaceutical innovation given the high costs and risks of drug development. Without patent exclusivity periods, companies would have no way to recoup their investments.
- Competition in the pharmaceutical industry drives improvements to existing drugs like increased efficacy, reduced side effects, better dosing, and new delivery methods. This benefits patients.
Presentation of CRAASH Barcelona, the new project of Biocat (Moebio Barcelona). The initiative is a 12-week program that helps European research teams launch successful device, diagnostic and e-/digital health innovations to improve health and patient care.
The document outlines the typical life cycle of a biotech startup company from founding through maturity. It shows how founders and early investors are initially involved at the startup stage when intellectual property is developed. As the company progresses, it requires growth capital from venture institutions and corporations to advance drug candidates. This results in dilution of the founders' stake but increases the overall valuation. Later in maturity, the company may pursue public capital or be acquired by large pharmaceutical companies once proof of concept data is established and a pipeline of candidates is in development.
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation by Lorraine Chiroiu, Chief Industry Affairs Officer
and Head of AusBiotech’s China Programs - AusBiotech Engaging with China
Presentation on:
- Facilitating medical devices trade with China by breaking down the major barriers to entry
- Providing information about intellectual property (IP) management in China and outline the types of business structures that are possible for Australian companies entering China
Presented at the Fortune Forum 2015 Australian Summit
Views for collaboration between pharmaceutical industry and academia a haapal...Antti Haapalinna
The document discusses views on collaboration between the pharmaceutical industry and academia from Antti Haapalinna, Vice President of Research and Development at Orion Corporation. It notes that strategic partnerships can cover the entire R&D chain from early discovery to late-stage clinical development and marketing. Early-stage partnerships are often with smaller organizations that provide specific expertise to complement larger companies. Later-stage partnerships are usually with larger organizations for their clinical trial expertise and global reach. Key success factors include a mutual desire to develop new treatments, each party contributing unique capabilities, and professionally coordinated collaboration.
ttopstart academy - getting NIH funding as a European researcher or companyttopstart B.V.
The NIH spends a lot of its research funding abroad, amongst which a significant portion in Europe. This presentation provides guidance for non-US entities to attract NIH funding.
This document provides information about an upcoming conference on managing partnerships with contract research organizations (CROs). The conference will take place on October 3-4, 2012 in London and will include presentations from pharmaceutical companies and CROs on trends in clinical development outsourcing, developing effective CRO partnerships, and managing regulatory inspections of CRO activities. Pre-conference workshops on October 2 will focus on defining the scope of CRO relationships and ensuring quality in CRO engagements. Key speakers are listed from pharmaceutical companies like Pfizer, Eli Lilly and AstraZeneca and CROs like Quintiles. The document outlines the conference agenda and encourages those in clinical development, outsourcing, and related areas to attend.
Preparing for a career inthe pharmaceutical industryMentLife
The document provides information about preparing for a career in the pharmaceutical industry. It discusses the pros and cons of working in the industry, some key statistics about the industry, and how the industry is changing and responding to challenges. It provides tips for how to prepare for an interview, improve chances of getting a job, and what skills are needed at different stages of the research and development process. The industry is still profitable but facing pressures to reduce costs through consolidation and outsourcing while demand for new drugs grows.
This document discusses strategies for pharmaceutical research and development (R&D) and drug development. Some key points:
- Developing a new drug takes 15-16 years on average and costs around $800 million, with 75% of costs attributed to high failure rates. Only 1 in 5-10 drugs that enter development make it to market.
- Patent protection is important for pharmaceutical innovation given the high costs and risks of drug development. Without patent exclusivity periods, companies would have no way to recoup their investments.
- Competition in the pharmaceutical industry drives improvements to existing drugs like increased efficacy, reduced side effects, better dosing, and new delivery methods. This benefits patients.
Presentation of CRAASH Barcelona, the new project of Biocat (Moebio Barcelona). The initiative is a 12-week program that helps European research teams launch successful device, diagnostic and e-/digital health innovations to improve health and patient care.
The document outlines the typical life cycle of a biotech startup company from founding through maturity. It shows how founders and early investors are initially involved at the startup stage when intellectual property is developed. As the company progresses, it requires growth capital from venture institutions and corporations to advance drug candidates. This results in dilution of the founders' stake but increases the overall valuation. Later in maturity, the company may pursue public capital or be acquired by large pharmaceutical companies once proof of concept data is established and a pipeline of candidates is in development.
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation by Lorraine Chiroiu, Chief Industry Affairs Officer
and Head of AusBiotech’s China Programs - AusBiotech Engaging with China
Presentation on:
- Facilitating medical devices trade with China by breaking down the major barriers to entry
- Providing information about intellectual property (IP) management in China and outline the types of business structures that are possible for Australian companies entering China
Presented at the Fortune Forum 2015 Australian Summit
The document discusses the need to organize pharmaceutical research and development differently by merging the strengths of academic and industrial drug research. It proposes creating a "Center for Open Innovation in Drug Discovery" (COIDD) to bring dedicated medicinal chemistry expertise to biological targets being studied in academia. Successful precedents for this type of center exist abroad, like the Vanderbilt Center for Neuroscience Drug Discovery, and it could place Radboud University at the forefront of translational medicine by advancing promising scientific discoveries toward clinical studies. The feasibility study would determine the focus, identify partners, and develop a business plan for creating a sustainable pharmaceutical research ecosystem through the COIDD.
This document provides an overview of Toni Rinow's presentation on corporate transactions. It discusses her experience in areas such as mergers and acquisitions, financing, deal sheets, and the global expansion risks associated with acquisitions. Specific examples discussed include acquisitions carried out by JSS Medical Research in Canada, India, Latin America, and Poland to expand their global clinical research presence. The presentation also covers business valuation methods and challenges of integrating acquired companies.
The document describes CIMIT's CRAASH program which helps healthcare innovators commercialize their technologies. CRAASH provides teams with mentors experienced in medical technology entrepreneurship to guide them through customer discovery and developing a business model. Over the course of the program, teams interview stakeholders, develop marketing strategies, and present their progress weekly. Most teams discover their solution may not be viable or require changes, but about 1/3 accelerate their path to market. Nearly all participating teams obtain funding within a year to further develop their solutions. The goal is to help innovators successfully navigate challenges of commercializing healthcare technologies.
Speid & Associates provides consultancy services to help speed new drugs to market. They have a team of expert consultants with experience in regulatory affairs, clinical development, drug development, and other areas. Their services include strategic planning, preparing regulatory submissions, conducting due diligence, assisting with clinical trials, and training company staff. They work with clients around the world to help achieve successful global drug registration.
This document provides an overview of the Centre for Drug Research and Development (CDRD), a Canadian non-profit organization that works to commercialize healthcare products. It has a network of over 50 research institutions and 10,000 investigators. CDRD takes discoveries from academic research through development milestones like validation and preclinical testing to commercialization via licensing, spin-offs, or co-development partnerships. It has advanced over 50 technologies toward commercialization and formed 7 spin-off companies. CDRD's pipeline includes projects in oncology, neuroscience, and other areas. Partnerships with industry, foundations, and governments are core to its success in bridging the gap between research and commercial products.
SMi Group's European BioNetworks SummitDale Butler
This document is a program for the "European BioNetworks Summit" conference on July 7-8, 2014 in London. The summit will bring together representatives from pharmaceutical, biotechnology, academic, and funding organizations to discuss strategic partnerships and collaborations. Over 12 speakers from companies like Novartis, Bristol-Myers Squibb, Bayer, and Johnson & Johnson will provide presentations on topics like developing business strategies, academic partnerships, pricing and reimbursement, and financing options. Attendees can network and learn how to create successful partnerships to increase innovation and research outcomes. A post-conference workshop on July 9th will focus on clinical development pathways.
Changing Paradigms in Outsourcing, Liz StonerConferenceForum
The document discusses changing paradigms in biotech outsourcing from an investor's perspective. [1] Traditionally, biotech companies tightly controlled outsourcing with strong internal oversight, but new models favor capital efficiency through increased reliance on contract research organizations (CROs). [2] Venture capital investors seek innovative projects with medical and economic potential that CROs can help develop on a lean budget. [3] Successful models involve CROs providing expertise while core decisions remain internal, allowing companies to remain virtually organized with fractional staff.
Paul Rohricht is a life sciences business development expert with nearly $500M in executed transactions. He has founded or co-founded 4 biotech startups, including Revivicor which was acquired by United Therapeutics. He has expertise in early stage technology commercialization for bio/pharma/med devices and startups. His background includes an MS, MBA from UPenn and over 20 years of experience in business development roles.
D. Glass Associates: Licensing, Tech Transfer and Strategic Patent ManagementDavid Glass
D. Glass Associates, Inc. offers expert assistance to academic institutions as well as biotechnology and medical device companies in the management of many aspects of the patent and licensing process and industry-academic relations.
Pitches from the 10 finalist teams selected to compete for the £100,000 Grand Prize of the inaugural OneStart competition in 2013, hosted by the Oxbridge Biotech Roundtable and SR One.
Learn more about this year's competition: http://oxbridgebiotech.com/onestart
Translate: Medical Technologies in the Leeds City Region is a new partnership of universities in the Leeds City Region with world-class expertise in the development of new medical technologies. Translate are working in partnership with DHEZ and the University of Bradford.
Agenda
* Introduction of Clinical Trial Country/Site Selection
* Select the Accredited Sites Outside China
* Understand the Submission Requirements in Targeted Countries (Authorized by CFDA)
* Challenges and Consideration to Conduct PK Bridging Study Outside China
* Estimation of the Patient Cost in Targeted Countries
* Conclusion on the Country/Site Selection
This document provides a summary of Paul Rohricht's professional experience and qualifications. It outlines his experience in business development, strategic planning, transaction structuring, and executive management roles in the biotechnology industry, with over $450 million in transactions completed. It details positions held at various biotech companies, including founding several startups, and highlights accomplishments such as negotiating licensing deals, securing funding, and growing revenues.
Panel discussion: Being a successful healthcare entrepreneur: lessons from Boston to Barcelona, with numerous experts from CIMIT, Boston, in economics, development and strategic planning of medical devices; in prototypes and patents and founders of several startups.
David Pritchard is a biopharmaceutical executive with extensive experience in business development, M&A, licensing, and strategic advisory services. He has held roles such as CEO, VP of business development, and independent consultant. Through these roles, he has completed numerous transactions involving licensing deals, acquisitions, and fundraising for companies in biopharma. He currently provides strategic and tactical advice to life sciences companies as an independent consultant.
The New Orleans BioInnovation Center is a $48 million facility that partners with LSUHSC and Tulane to support the commercialization of biotechnologies in the region. It provides lab space, funding assistance, and business programming to 50 technology companies. Examples include NuMe Health, which is developing prebiotics for health conditions, and MiniVax, which received an NIH grant for vaccine development. The Center aims to continue growing the entrepreneurial culture and research base in the region while addressing challenges around workforce, capital, and retaining startup companies.
Swaroop Vakkalanka provides an overview of starting a discovery-based R&D company in India. He discusses the background of pharmaceutical R&D globally and in India, opportunities for a business model, gaps that need to be addressed, the importance of licensing, and factors for success regarding infrastructure and operations. Key points include diminishing R&D productivity globally, India's progression from generics to biotech, gaps in India's capabilities, and the need for management experience, flexibility, financial support, and a focus on science in early-stage R&D.
The document summarizes an accelerator program that efficiently identifies, evaluates, and develops emerging biotechnologies. It has had success funding 10 companies since 2003, with over $187 million raised for investments. The accelerator provides world-class resources like scientific expertise, venture capital funding, management support, and lab facilities. It utilizes proprietary deal flow from sources like the Institute for Systems Biology and its network of investors and scientists. The rigorous process involves technical and IP due diligence before making milestone-based investments in companies with promising technologies that are too early for independent venture funding.
Market Analysis of Clinical Research in Asia PacificClinActis Pte Ltd
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
The document discusses the need to organize pharmaceutical research and development differently by merging the strengths of academic and industrial drug research. It proposes creating a "Center for Open Innovation in Drug Discovery" (COIDD) to bring dedicated medicinal chemistry expertise to biological targets being studied in academia. Successful precedents for this type of center exist abroad, like the Vanderbilt Center for Neuroscience Drug Discovery, and it could place Radboud University at the forefront of translational medicine by advancing promising scientific discoveries toward clinical studies. The feasibility study would determine the focus, identify partners, and develop a business plan for creating a sustainable pharmaceutical research ecosystem through the COIDD.
This document provides an overview of Toni Rinow's presentation on corporate transactions. It discusses her experience in areas such as mergers and acquisitions, financing, deal sheets, and the global expansion risks associated with acquisitions. Specific examples discussed include acquisitions carried out by JSS Medical Research in Canada, India, Latin America, and Poland to expand their global clinical research presence. The presentation also covers business valuation methods and challenges of integrating acquired companies.
The document describes CIMIT's CRAASH program which helps healthcare innovators commercialize their technologies. CRAASH provides teams with mentors experienced in medical technology entrepreneurship to guide them through customer discovery and developing a business model. Over the course of the program, teams interview stakeholders, develop marketing strategies, and present their progress weekly. Most teams discover their solution may not be viable or require changes, but about 1/3 accelerate their path to market. Nearly all participating teams obtain funding within a year to further develop their solutions. The goal is to help innovators successfully navigate challenges of commercializing healthcare technologies.
Speid & Associates provides consultancy services to help speed new drugs to market. They have a team of expert consultants with experience in regulatory affairs, clinical development, drug development, and other areas. Their services include strategic planning, preparing regulatory submissions, conducting due diligence, assisting with clinical trials, and training company staff. They work with clients around the world to help achieve successful global drug registration.
This document provides an overview of the Centre for Drug Research and Development (CDRD), a Canadian non-profit organization that works to commercialize healthcare products. It has a network of over 50 research institutions and 10,000 investigators. CDRD takes discoveries from academic research through development milestones like validation and preclinical testing to commercialization via licensing, spin-offs, or co-development partnerships. It has advanced over 50 technologies toward commercialization and formed 7 spin-off companies. CDRD's pipeline includes projects in oncology, neuroscience, and other areas. Partnerships with industry, foundations, and governments are core to its success in bridging the gap between research and commercial products.
SMi Group's European BioNetworks SummitDale Butler
This document is a program for the "European BioNetworks Summit" conference on July 7-8, 2014 in London. The summit will bring together representatives from pharmaceutical, biotechnology, academic, and funding organizations to discuss strategic partnerships and collaborations. Over 12 speakers from companies like Novartis, Bristol-Myers Squibb, Bayer, and Johnson & Johnson will provide presentations on topics like developing business strategies, academic partnerships, pricing and reimbursement, and financing options. Attendees can network and learn how to create successful partnerships to increase innovation and research outcomes. A post-conference workshop on July 9th will focus on clinical development pathways.
Changing Paradigms in Outsourcing, Liz StonerConferenceForum
The document discusses changing paradigms in biotech outsourcing from an investor's perspective. [1] Traditionally, biotech companies tightly controlled outsourcing with strong internal oversight, but new models favor capital efficiency through increased reliance on contract research organizations (CROs). [2] Venture capital investors seek innovative projects with medical and economic potential that CROs can help develop on a lean budget. [3] Successful models involve CROs providing expertise while core decisions remain internal, allowing companies to remain virtually organized with fractional staff.
Paul Rohricht is a life sciences business development expert with nearly $500M in executed transactions. He has founded or co-founded 4 biotech startups, including Revivicor which was acquired by United Therapeutics. He has expertise in early stage technology commercialization for bio/pharma/med devices and startups. His background includes an MS, MBA from UPenn and over 20 years of experience in business development roles.
D. Glass Associates: Licensing, Tech Transfer and Strategic Patent ManagementDavid Glass
D. Glass Associates, Inc. offers expert assistance to academic institutions as well as biotechnology and medical device companies in the management of many aspects of the patent and licensing process and industry-academic relations.
Pitches from the 10 finalist teams selected to compete for the £100,000 Grand Prize of the inaugural OneStart competition in 2013, hosted by the Oxbridge Biotech Roundtable and SR One.
Learn more about this year's competition: http://oxbridgebiotech.com/onestart
Translate: Medical Technologies in the Leeds City Region is a new partnership of universities in the Leeds City Region with world-class expertise in the development of new medical technologies. Translate are working in partnership with DHEZ and the University of Bradford.
Agenda
* Introduction of Clinical Trial Country/Site Selection
* Select the Accredited Sites Outside China
* Understand the Submission Requirements in Targeted Countries (Authorized by CFDA)
* Challenges and Consideration to Conduct PK Bridging Study Outside China
* Estimation of the Patient Cost in Targeted Countries
* Conclusion on the Country/Site Selection
This document provides a summary of Paul Rohricht's professional experience and qualifications. It outlines his experience in business development, strategic planning, transaction structuring, and executive management roles in the biotechnology industry, with over $450 million in transactions completed. It details positions held at various biotech companies, including founding several startups, and highlights accomplishments such as negotiating licensing deals, securing funding, and growing revenues.
Panel discussion: Being a successful healthcare entrepreneur: lessons from Boston to Barcelona, with numerous experts from CIMIT, Boston, in economics, development and strategic planning of medical devices; in prototypes and patents and founders of several startups.
David Pritchard is a biopharmaceutical executive with extensive experience in business development, M&A, licensing, and strategic advisory services. He has held roles such as CEO, VP of business development, and independent consultant. Through these roles, he has completed numerous transactions involving licensing deals, acquisitions, and fundraising for companies in biopharma. He currently provides strategic and tactical advice to life sciences companies as an independent consultant.
The New Orleans BioInnovation Center is a $48 million facility that partners with LSUHSC and Tulane to support the commercialization of biotechnologies in the region. It provides lab space, funding assistance, and business programming to 50 technology companies. Examples include NuMe Health, which is developing prebiotics for health conditions, and MiniVax, which received an NIH grant for vaccine development. The Center aims to continue growing the entrepreneurial culture and research base in the region while addressing challenges around workforce, capital, and retaining startup companies.
Swaroop Vakkalanka provides an overview of starting a discovery-based R&D company in India. He discusses the background of pharmaceutical R&D globally and in India, opportunities for a business model, gaps that need to be addressed, the importance of licensing, and factors for success regarding infrastructure and operations. Key points include diminishing R&D productivity globally, India's progression from generics to biotech, gaps in India's capabilities, and the need for management experience, flexibility, financial support, and a focus on science in early-stage R&D.
The document summarizes an accelerator program that efficiently identifies, evaluates, and develops emerging biotechnologies. It has had success funding 10 companies since 2003, with over $187 million raised for investments. The accelerator provides world-class resources like scientific expertise, venture capital funding, management support, and lab facilities. It utilizes proprietary deal flow from sources like the Institute for Systems Biology and its network of investors and scientists. The rigorous process involves technical and IP due diligence before making milestone-based investments in companies with promising technologies that are too early for independent venture funding.
Market Analysis of Clinical Research in Asia PacificClinActis Pte Ltd
ClinActis Pte Ltd is a full service CRO providing clinical trial services to the pharmaceutical, medical device, medical nutrition and biotech companies in Asia Pacific. Established in 2009, ClinActis Pte Ltd is headquartered in Singapore.
ClinActis Experience
• 33 years experience in clinical research in pharmaceutical and biotechnology companies as well as CROs
• 27 years experience in Asia Pacific, including Australia/New Zealand, China, Malaysia, Hong Kong, India, Indonesia, The Philippines, Singapore, South Korea, Taiwan, Thailand and Japan
• Extensive knowledge of regulatory frameworks, best KOLs and sites across the region
• Vast therapeutic experience including Cardiovascular, CNS, Endocrinology, Infectious diseases, Oncology, and Respiratory
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
How True Open Innovation TM and its global network can expand the opportunity for drug development by increasing efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
The 3rd Annual Investigator Initiated and Sponsored Research conference will take place January 21-22, 2015 in Philadelphia, PA. The conference will provide insights from industry leaders on building standards for determining fair market value, transparency, and reporting practices for investigator initiated studies, investigator sponsored trials, and cooperative group research. Participants can choose from in-depth workshops, breakout sessions, and think tanks on optimizing global research, conducting fair market value analysis, leveraging master protocols, and developing tactics for negotiating investigator initiated study agreements. The goal is to create a platform for developing standards in these important areas of clinical research.
The Entrepreneur's Guide to Hospital Partnerships by @Rock_HealthRock Health
A living document and initial guide for entrepreneurs as they navigate partnering with health providers, initially compiled after 22 interviews with entrepreneurs, hospital administrators, investors, lawyers, clinicians and researchers. Purchase the report here: https://gumroad.com/l/qgUT
The document discusses innovation with commercial electronic health records (EHRs) at Partners HealthCare. It describes Partners HealthCare's structure and approach to innovation, which includes advancing core work and creating new solutions. The clinician team focuses on areas like clinical process redesign, clinical informatics, and knowledge management. Guiding principles for fostering innovation emphasize supporting innovators, prioritizing innovations aligned with Partners' strategy, and disseminating innovations across Partners HealthCare. A prioritization framework is being created to evaluate innovative projects according to standard criteria.
Karen Livingstone - ECO 17: Transforming care through digital healthInnovation Agency
The document discusses the Innovation Exchange and SBRI Healthcare programs which aim to accelerate the development and adoption of innovative healthcare solutions in England. It provides background on Karen Livingstone, the director of the programs. It then outlines key forces shaping global healthcare and describes the 15 Academic Health Science Networks that work locally and nationally to drive innovation adoption across England. The rest of the document details how the Innovation Exchange identifies healthcare needs and supports companies through funding competitions, needs assessments, and providing support to help ready solutions for adoption across the NHS. It provides examples of companies it has supported in areas like patient engagement, chronic condition management, and early disease detection.
The document discusses how True Open Innovation and Boston Strategics' global network can improve drug development efficiency and lower costs. It outlines challenges in the pharmaceutical industry like decreased productivity and increased costs. It then describes how Boston Strategics uses a virtualized model and worldwide expert network to assemble project teams that can progress drug candidates through development faster and at lower expense than traditional models. Examples are provided of projects demonstrating savings of time and money. The goal is to establish an open innovation platform to facilitate drug development collaborations globally.
The document discusses investment strategies for the life science industry in India. It provides an overview of India's economic growth, pharmaceutical industry, and drivers in the industry such as population growth and increasing chronic diseases. It outlines strengths and weaknesses of India's pharmaceutical sector. It also discusses internal R&D programs by Indian pharmaceutical companies, discovery and commercialization deals between Indian and global companies, and recent acquisitions in the Indian life science industry. The presentation aims to translate India's potential in the life science sector into reality through strategic investments.
The document describes TSRL Inc.'s Technology Accelerator program, which aims to help move therapeutic assets past the "Valley of Death" by providing infrastructure, scientific and business resources, and funding to drive projects from pre-clinical development to an Investigational New Drug application. The accelerator selects potential drug candidates based on criteria to maximize commercialization potential and provides services like project management, drug development expertise, and access to networks to help obtain funding and partners. The goal is to generate necessary data packages and commercialization plans to support projects reaching their next development milestones.
Bio dinner presentation 2016 plus about one nucleusTony Jones
With One Nucleus Corporate Sponsor Amgen acting as host, 5th June saw the largest and most diverse One Nucleus BIO Executive Dinner yet. The presentation sets out the what, why and who along with background information on One Nucleus and the London-Cambridge Life Science Cluster
Biotechnology consulting refers to the practice of organization involved in Pacificlinkconsulting services contact: San Diego, CA 92127 Phone: 858-335-1300
The Cell Therapy Catapult was established to help grow the UK's cell therapy industry by addressing barriers to development and commercialization. It provides facilities, expertise, and funding to move cell therapy candidates through development towards clinical trials and commercialization. The Catapult has established GMP manufacturing assessment capabilities, aims to complete 150-200 projects in its first 5 years, and seeks to create 2-4 significant investible cell therapy propositions to help build a £10 billion industry in the UK.
hitt services gives a multiple range of advising, projects and support that covers the main needs of knowledge of all actors in healthcare market.We design easier and more profitable ways for:
• To generate primary research in health services
• To support start-ups on their business strategy &development
• To build and consolidate strategic decisions in market access for health products & services
Chelation Partners is solving sepsis with DIBI, and iron binding polymer that augments a natural defense to infections. It slows infections and the over-reaction of the immune system known as cytokine storm, which kills patients. It is immune to antibiotic resistance and effective against a very broad spectrum of disease causing microorganisms.
A life sciences consulting firm based in Chicago, Aagami Inc., offers strategic consulting, technology licensing, and business/market research services to support global biotech, pharmaceutical, medical device, and consumer health companies in their initiatives with India and Asia. The document provides details on Aagami's services, approach, clients, leadership team, and case studies highlighting strategic partnerships and licensing deals facilitated by Aagami that helped clients establish partnerships and reduce costs in emerging markets.
This document discusses the challenges of precision medicine and drug discovery, including vast amounts of biological data, high costs of R&D, and lack of standards. It proposes a new model called Symbiotic Innovation that establishes vertically integrated organizations headed by expert task forces to source internal and external competencies. This model aims to improve ROI through collaborative projects, proprietary databases, and potentially spinning off high-risk projects to new companies.
Vitargent is a Hong Kong-based biotechnology company that provides testing services and products to assess the impact of estrogenic chemicals and other pollutants. It has established several reference cases working with cosmetics companies and testing labs. Vitargent launched an "estrogen safe mark" and obtained accreditation making it the only lab in Asia that can provide certain toxicity testing. It is seeking strategic partners to help promote its programs, develop testing standards, and potentially pursue an IPO. Vitargent's services and products assess chemicals/pollutants like dioxins and it utilizes transgenic fish models to detect estrogenic substances in products like food, drugs, and the environment.
Presentation at mHealth Israel Investors Summit by Tom Sudow, Head of Business Development: "Successful Commercialization – The Cleveland Clinic Story". The mission is to promote Innovation via Commercialization by bringing new innovations into widespread clinical practice, protecting the intellectual property underlying the innovations, optimizing the value returned for those innovations, and growing the regional economy.
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfrightmanforbloodline
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
1. Ventac Partners
VC/PE Investment & Strategic Partnerships in China
Melya Hughes Crameri, Ph.D.
Ventac Partners – London
mcrameri@ventac-partners.com
+44 7415 572 682
Jonathan Myers, BSc., MBA
Ventac Partners – Shanghai
jmyers@ventac-partners.com
+86 13601989842
+1 (415) 202-3211
Scott Woodward
Ventac Partners – San Francisco
swoodward@ventac-partners.com
+1 (415) 720 5800
Randy Berholtz
Ventac Partners – San Diego
rberholtz@ventac-partners.com
+1 (858) 205-5091
2. 2
Table of Contents
• China – A Tremendous Opportunity
- Market Overview
- Cross Border Transactions
• About Ventac Partners
- Global Business
- Portfolio Companies
- China Business
• The Ventac Team
• Ventac’s Track Record – Life Science Transactions
• Ventac’s China Venture Capital Relationships
• Summary - Why China? Why Ventac?
• Appendix
- Examples of Cross-Border Transactions
- Shanghai Partner Bio
- Global Partners
3. 33
China - Tremendous Opportunity
• Life Science in China is Booming –
– China’s life science industry has been
growing at approximately 10-20% per year.
– #1 market in the world by 2020
– Massive government incentives
– Large pool of returnees that have come
back to China to start new businesses
• Cross Border Deal Activity is Strong -
– More than 85% of all partnerships in China
over the last several years.
– 90% cross border in 2015
– Flow of technology primarily into China
– $1.8B in partnering deals in 2014
– $4.2B in 2015
– 31% preclinical => significant early stage
– Licensing deals: 58%, Co-development: 23%
– Deal terms improving rapidly
• China VCs – Investing in Western Cos.
– VC - $1.7B in 2014, $1.8B in 2015
– Cross border investment is happening
Source: World Bank, IMS, McKinsey, MOFCOM, CASS, CADF, NHFPC, ChinaBio
4. 4
China – Massive Government Support
• Chinese government committed $125
billion for health care reforms:
• Expanding insurance coverage
• Improving healthcare systems
• Promoting universal coverage
• The 12th Five Year Plan (‘11-’15) dedicated 33%
of total budget to healthcare spending
• Traditional Chinese Medicine products
outnumber NCEs by ~3:1
• Recognized need to shift away from TCM
to more modern, effective treatments
• Recognized need to tackle certain disease
areas, such as infectious disease (both
bacterial and viral), in order to promote
general welfare
5. 5
China – Wide Range of Cross Border Deals
• Venture Capital Investment
• Corporate Investment
• Rx, Dx, Med. Devices, Formulation
• Improving Deal Terms as Competition
Increases
• In-bound
• Out-bound
• Research Institute – Discovery Platform Co.
• Research Institute – CRO
• Chinese Co. – US University
• Chinese Co. – US JV with University
Investment
Licensing &
Partnering
M&A
Drug
Discovery
University
Tech-Trans.
Please see the appendix for specific examples.
6. 66
About Ventac Partners
• Global consulting and transaction company
• Dedicated to life science
• Headquartered in Copenhagen, Denmark
• Grow our own portfolio of startups with several
successful exits to date
• 19 partners in N. America, Europe and Asia
• 7+ years experience in China (via Nine Bridges Capital)
• Experts in Life Science corporate/business development
7. 77
19 Partners and 13 Offices on 3 Continents
Lund
Copenhagen
Basel
Madrid
San Diego
Boulder
Boston
Munich
Trondheim
Düsseldorf
Shanghai
San Francisco
London
8. 88
Ventac’s Global Business
Strategic Partnerships – Buy and Sell Side
- Pharma, SMEs, Tech-Transfer
- All subsectors of Life Science
- Licensing, JVs, M&A, virtually all deal structures
Venture Capital Fundraising
- Rx, Dx, Medical Devices, Healthcare IT
- All subsectors of Life Science
Ventac Portfolio Companies
- Europe, Asia
Market Research
- Analysis of therapeutic/diagnostic/medtech areas in
various territories
- Mapping of companies/products
- Market opportunity assessments
BD&L Training Workshops
- Life Science Executives
- University Post-graduates / Post-Docs / Tech Transfer
8
9. 9
Ventac Portfolio Companies
• Spin out from Norwegian UST & Oslo University
• Focuses on chronic inflammatory disorders. Currently in Phase
II for psoriasis. Preclinical development programs in
glomerulonephritis and rheumatoid arthritis
• Partnering discussions ongoing
• Spin-out from the Biomedical Centre (BMC) at Lund University,
Sweden
• Developing a tolerogenic vaccine – a unique treatment concept
for inducing immune tolerance.
• Orphan designation by the EMA
• Currently in pre-clinical development
• Listing on stock exchange in Sweden in June 2015
10. 10
Ventac Portfolio Companies
• Spin-out from the Norwegian University of Science
and Technology, Norway, dedicated to develop novel
anti-cancer agents targeting DNA repair and cell
cycle control
• Currently in CTA/IND-stage
• Recently completed series B financing round
• Spin-out from AMC, Holland, developing novel
treatments for immune mediated and
neurogenerative disorders
• Currently in late pre-clinical development
• Recently completed series B financing round
11. 1111
Ventac Portfolio Companies
• Spin-out from the Cancer Research Foundation in
Denmark
• Currently develops a therapeutic vaccine against
NSCLC; will enter phase I clinical testing in 2017
• Listed in the stock exchange in Sweden in 2016
• Swiss company based on a technology licensed
from the Hellenic Pasteur Institute, Greece.
• Currently in pre-clinical development with an
antibody against extracellular hsp90 target
• Looking for Series A funding
12. 12
Ventac’s China Business
Strategic Partnerships – Buy and Sell Side
- Pharma, SMEs, Tech-Transfer
- All subsectors of Life Science
- Licensing, JVs, M&A, virtually all deal structures
Venture Capital Fundraising
- Rx, Dx, Medical Devices, Healthcare IT
- All subsectors of Life Science
13. 13
Ventac’s China Team
• Ventac Partners currently has
19 partners and 13 offices
across North America,
Europe, and Asia
• All with previous industry
experience in strategy and
operations, executive and
non executive management,
and/or extensive fund
raising, business
development and deal
making track records
• Partners brought into a
project as needed, including
potentially a full turn-around
or M&A team, enabling
Ventac to efficiently scale up
or down as needed
• Mikael Oerum – Copenhagen
• Founder, Ventac Partners
• Current CEO, Avexxin
• Board Chair, HUNT Biosciences, others
• Jonathan Myers – Shanghai
• Former BD, Pain Tx, Onyx, Chiron, Roche
• Numerous transactions worldwide
• Expert in Life Science Valuation
• BSc., Chemical Engineering
• MBA, Rotterdam SOM, Erasmus Univ.
• Randy Berholtz – San Diego
• General Counsel to ACON Group from
Hangzhou
• Extensive China fundraising experience
• Venture Capital COO and Senior Advisor
• Experience in partnering in the pharma,
device and Dx fields field in China
• Extensive knowledge of Chinese IP, law and
litigation
14. 14
Ventac’s China Team
• Melya Hughes Crameri, PhD – London
• Strategic Advisor to numerous US &
European life science companies
• Previously Founder & CEO of Evolva Inc.
& EVP Evolva SA (EVE.SW - $50M risk
capital raised and $80M non-dilutive)
• Extensive experience in negotiation
• Neil Thomas – Madrid & London
• 19 years executive and board level
experience in biotech and medtech.
• Investee company experience in 5 VC
funding rounds totaling $117m USD
• PhD, University of Durham, UK
• Joseph Tucker - Boston
• Current CEO, Epimeron
• Former CEO, Taiga Bioactives,
Pharmavation, Stem Cell Therapeutics
• Ph.D. Univ. of Calgary
15. 15
Ventac’s China Team
• Dede Willis – Boulder
• 30 years in startups and turnarounds
• Board Member Panion Animal Health AB
• CEO Orbit Genomics (incorporating soon)
• Former Co-founder and COO Boulder
Diagnostics Inc (now Oxford Immunotec)
• Former CEO Proligo Biochemie GmbH
and VP Operations Proligo LLC
• B.Sc. Chemical Engineering, MBA
• Scott Woodward – San Francisco
• 20 years in various Healthcare
Leadership Roles
• Global VP-Biomarker Operations for a US
Headquartered multi-national CRO
• Extensive dealmaking experience in
private equity and pharma
16. Ventac Partners Global Track Record
Financing * M&A *
$200,000,000
Strategic Alliance &
License
2006
Licensing *
$900,000,000 $380,000,000
2009
$11,500,000
2013
$58,500,000
2010
$500,000,000
2011
$917,000,000
2013
$50,000,000
2006
$450,000,000
Acquisition by
2014
$7,500,000
Merged with
2003
$21,800,000
2013
$348,000,000
2013
$1,800,000,000
2013
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Strategic Alliance &
License
Series B
2007
2008
$30,000,000
2007
$14,000,000
2012
Series C
F-1 Prepared
2014
Preparation for IPO at
NASDAQ
Dual Track / M&A by
Roche
Series D
$Not disclosed
2007
Co-ownership & License
Professor Imanishi &
Pantheco
$Not disclosed
Acquisition of 8 drugs
2013
This
image c
This
image c
This
image c
$6,700,000
2012
Strategic Alliance &
License
$10,000,000
2000
Private Placement to a
consortium of Nordic
Investors
Lead Manager
$13,000,000
2001
Private Placement to a
consortium of Nordic
Investors
Sole Manager
$Not disclosed
2000
Worldwide rights to
LNA technology
$180,000,000
2000
Worldwide semi-exlusive
manufacturing rights to
LNA technology
$Not disclosed
2000
Use of LNA in clinical
diagnostics
€23,000,000
2004
€10,500,000
2006
€17,000,000
2003
Series B
Private Financing
Series C
Private Financing
Private Financing
$400,000,000
2005
Strategic Alliance
&
License
$4,000,000
2014
Series A
$10,300,000
2006
Series A
(2nd
closing)
$47,000,000
2009
Series B
$35,000,000.
2000
Novartis Research
Foundation
Partnership
$Not disclosed
Merged with
2014
$Not disclosed
Acquisition of
2014
$700,000,000
2007
€27,200,000
2007
€27,000,000
2009
Series B Series C
Summary
Licensing Deals - 18 deals done (3 not disclosed), valued at $6.45B+
Financings - 14 deals done (1 not disclosed) valued at $296M+
M&A - 5 deals done (3 not disclosed) valued at $458M+
16
17. 1717
Ventac Partners China Track Record
Closed & Ongoing Deals:
– Funding - $35M raise for private US Rx company from Chinese large pharma.
– Funding - $10M+ raise for Ventac affiliate from large China Dx company
– Funding/Option - $2 million with large Chinese investment company and also provided the
company with an exclusive option for Chinese rights
– M&A – Sold immunoassay business line to US multi-national company for $450 million
– M&A - Purchased a private US pharmaceuticals company with an oncology drug for $25 million
upfront plus over $100 million in milestones
– Co-development – Several R&D collaborations with large international pharma companies worth
over $150 million
– License – License with Swiss pharma company for over $75 million for cell based Dx
– Litigation - Engaged in multi-million dollar international patent litigation
– Distribution – several deals in Dx space
– Clinical trials - arranged multiple site Phase III study in Chinese - female sexual dysfunction
– Ongoing – Term sheet stage with cross border license in wound care space (device)
– Others – Not Closed: Fertility Dx, Cancer Dx, Cancer Rx
China Consulting Projects:
– Valuation of China Rx opportunities in diabetes, breast cancer, NSCLC space
– Evaluation of HK life science ecosystem – HK Government
Details can be shared under confidentiality
18. 18
China VC Relationships
• We maintain an active
database of 100+ life
science investor
relationships
• These firms are on our
“First To Call” List
• Other investors include:
– W.I. Harper
– Mingly China Growth Fund
– DFJ Dragon Fund
– Mustang Ventures
– Mitsui Global Investment
19. 19
PE Relationships & Targets
• Ventac’s China
focused PE
relationships and
targets include the
following.
• Some are PEs, while
others are VC/PE
hybrids
• Some PE investors,
such as Milestone
Capital, will
syndicate PE
investments
20. 20
Why China? Why Ventac?
• The Time for China is Now
– Market is growing, deal terms are improving and China is
hungry for good Western technology
• China is Not Without Risk
– IP theft, unethical business practices, poor manufacturing,
corrupt regulatory/certification processes and fluid rule of law
are typical problems
– Ventac will guide you to work with the best people and
companies
• Ventac Can Help Your Company With Virtually All Cross
Border Transactions in China Life Science
– Experience with just about any deal structure you can imagine,
including VC funding, licensing, joint ventures, M&A,
divestitures tech-transfer agreements, strategic partnerships
and so on
Strong
Demand
Strong
China
Demand
China Is
Complex
Ventac
China
Ventac
Knows
China
21. 21
Ventac Partners
Please Contact Us
Melya Hughes Crameri, Ph.D.
Ventac Partners – London
mcrameri@ventac-partners.com
+44 7415 572 682
Jonathan Myers, BSc., MBA
Ventac Partners – Shanghai
jmyers@ventac-partners.com
+86 13601989842
+1 (415) 202-3211
Scott Woodward
Ventac Partners – San Francisco
swoodward@ventac-partners.com
+1 (415) 720 5800
Randy Berholtz
Ventac Partners – San Diego
rberholtz@ventac-partners.com
+1 (858) 205-5091
23. 23
Examples of Cross-Border Transactions
• Cross Border Financings:
– Case 1 – VC Investment:
– Investor: Lilly Asia Ventures
– Portfolio Company: Crown Biosciences
– Deal Summary: Crown Bioscience closed a $26.6 million Series D funding round led by
Lilly Asia Ventures Fund II. CrownBio is a preclinical CRO, specializing in oncology and
metabolic disorders, headquartered in California with labs in Beijing, Taicang (China), the
UK and North Carolina. CrownBio said it would use the money to expand its platform
technologies and make acquisitions. (May, 2014)
– Case 2 – VC Investment:
– Investor: BVCF
– Portfolio Company: MicuRx Pharmaceuticals
– Deal Summary: MicuRx Pharmaceuticals, a San Francisco-Shanghai antibiotics company,
raised $25 million in Series B financing (see story). The round was led by BVCF (formerly
BioVeda) and joined by previous investors Morningside Group and Devon Park
Bioventures. The proceeds will be used to fund the US-China development of MRX-I,
which has completed a Phase I clinical trial in China. MRX-1 is a novel oral oxazolidinone
antibiotic that targets drug-resistant infections. (August, 2013)
24. 24
• Cross Border Licensing Deals
– Case 1 – Drug Development:
– Licensee: Zhejiang Hisun, China
– Licensor: Celsion, USA
– Deal Summary: Zhejiang Hisun licensed Thermadox, a liposomal formulation of
doxorubicin for primary liver cancer. Terms included: $5M Option Payment Upfront,
$5M Payment after exercising the Option, $25M License upfront (net $15M after
deducting option payments), $55M in R&D Milestones, $45M in Sales Milestones, Tiered
double digit royalties. (January, 2013)
– Case 2 – Drug Formulation:
– Licensee: Sihuan Pharma, Hong Kong
– Licensor: to-BBB, Netherlands
– Deal Summary: Sihuan to perform feasibility studies on certain of Sihuan’s existing drugs
in to-BBB’s G-Technology® delivery system . If successful, the tests will lead to a
collaborative effort to develop one or more compounds. The G-Technology® - delivery
system allows drugs to cross the blood-brain barrier and, at the same time, facilitates
sustained release of the active ingredients. (December, 2013)
Examples of Cross-Border Transactions
25. 25
• Cross Border Discovery Collaborations:
– Case 1 - Research Institute-CRO:
– Partner 1: Shanghai Institute of Materia Medica (SIMM), China
– Partner 2: Crown Bioscience, USA
– Deal Summary: As a first step, the two entities will build the world’s largest mouse
clinical trial center by combining their collections of patient-derived xenograft (PDX)
models. Then, using Crown’s oncology discovery and translational capabilities, the
center will accelerate development of SIMM’s oncology drug candidates. Crown is a US-
headquartered CRO with its lab operations in China. (November 2013)
– Case 2 – Research Institute-Drug Discovery Company:
– Partner 1: iHuman Institute at ShanghaiTech University, China
– Partner 2: RuiYi, US/China
– Deal Summary: RuiYi, a San Diego-Shanghai innovative drug discovery company, formed
a research collaboration with iHuman Institute at ShanghaiTech University (see story).
The collaboration will use RuiYi's iCAPS technology to create novel monoclonal
antibodies. Ray Stevens, PhD, a structural biologist at San Diego’s Scripps Institute, is the
Founding Director of the iHuman Institute and the Scientific Founder of RuiYi. In
addition, RuiYi announced that it closed a $4 million debt financing from Silicon Valley
Bank. (June, 2014)
Examples of Cross-Border Transactions
26. 26
• Cross Border Mergers & Acquisitions:
– Case 1 - Clinical CRO acquires preclinical CRO:
– Acquirer: Tigermed, China
– Target: Frontage Labs, USA/China
– Deal Summary: Hangzhou Tigermed Consulting (SHE: 300347), a China clinical-stage
CRO, will add pre-clinical capability to its service offerings by paying $50.2 million to
acquire a 70% stake in Frontage Labs, headquartered in Pennsylvania. Frontage Labs
provides both pre-clinical and clinical CRO services through its facilities in Pennsylvania
and the Zhangjiang Hi-Tech Park in Shanghai. Tigermed said Frontage would continue to
operate independently, with its current management team, led by CEO Dr. Song Li,
remaining intact. (May 2014)
– Case 2 – Medical Devices Acquisitions:
– Acquirer: Shanghai Fosun, China
– Targets: Several Israeli Medical Devices Companies
– Deal Summary: Shanghai Fosun Pharma (SHE: 600196; HK: 02196) is planning to acquire
a number of Israeli medical device companies, and has already begun due diligence on
several, according to the company’s CEO, Fang Yao. The news comes one year after
Fosun paid $240 million to acquire Alma Lasers, an Israeli company that makes high-end
wrinkle-smoothing devices. Fosun may incorporate all of its acquired Israeli operations
under Alma, said Yao. (June, 2014)
Examples of Cross-Border Transactions
27. 27
• Cross Border University Collaborations:
– Case 1 - China-USA University Collaboration:
– Company: HD Biosciences, China
– University: Marshall University, USA
– Deal Summary: HD Biosciences, a Shanghai drug development CRO, will partner with
Marshall University of West Virginia to develop innovative treatments for cancer. The
partners will share the costs of discovery and development of the drugs, and they will
also own IP and commercialization rights jointly. The Marshall Institute for
Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of
Medicine will be HD Biosciences’ partners. (July 2014)
– Case 2 – JV in US to Develop University Technologies:
– Companies: Gloria Pharma, China, Cumberland Pharma, USA
– University: Vanderbilt University, USA
– Deal Summary: Harbin Gloria Pharma (SHE: 002437), a China injectable drugmaker, has
joined Cumberland Pharma (NSDQ: CPIX) of Tennessee in Cumberland Emerging
Technologies, a translational R&D effort. Both companies have made $1 million
investments in CET, though Cumberland remains the majority owner. Gloria will have the
right of first refusal on China rights to CET’s product candidates, which are discovered at
Vanderbilt University in Nashville and other regional research centers. (May, 2014)
Examples of Cross-Border Transactions
28. 28
Ventac Partner Bio - Shanghai
Jonathan Myers, BSc., MBA
• Jonathan, who has lived and worked on four continents, has 17+ years
experience in VC fundraising as well as phases of pharma/biotech
transactions, from initial screening to due diligence to valuation,
negotiation and closing. This experience includes practically all deal
structures, including in-licensing, out-licensing, joint ventures, and mergers
& acquisitions.
• Prior to Ventac Partners, Jonathan was Founder and Managing Director of
Nine Bridges Capital, a Shanghai based life science financial advisory and
business development consulting firm. Jonathan has also worked in various
business development and corporate finance roles pharma/biotech
industry in the San Francisco Bay Area and in Basel, Switzerland for
companies including Pain Therapeutics, Onyx Pharmaceuticals Chiron
Corporation and Roche. Jonathan worked on over 50 deals during his time
in the Bay Area and accomplishments of note include the completion of a
$400M out-licensing deal as well as various in-licensing deals, drug
formulation deals, manufacturing deals and option agreements. Jonathan
began his pharma/biotech career in a hybrid corporate finance/business
development role, building valuation models in support of deal negotiation
and running the due diligence process for many deals at Chiron
Corporation.
• Prior to receiving his MBA from the Rotterdam School of Management,
Erasmus University, Jonathan was a chemical process engineer with Nobel
Industries (Akzo Nobel), in Sweden, Chile and the United States, having
received is BSc degree in chemical engineering from Michigan State
University.